Pfizer & Moderna – two very different companies President Biden’s goal to vaccinate between 70% and 85% of the U.S. population, which is roughly 230
Revive Therapeutic (RVV.C) announced they have received positive results from a pre-clinical study evaluating the efficacy of psilocybin for the treatment of mild traumatic brain injury (TBI) in
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically
Humming in Q1 I’ve had a rough year, but Revive (RVV.C) sure hasn’t. With a portfolio based around psychedelics, cannabis, and diseases – this company
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual
Mother nature Am I a true hippy, or do I have an impulsive personality that morphs and changes due to a lack of identity? My
Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today,
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space.
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
One of the unfortunate downsides of living in the 21st century is the fact that most of us will have to deal with cancer in
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks
Revive Therapeutics (RVV.C) recent supply agreement with HAVN Life Sciences (HAVN.C) will give them a steady supply of naturally derived psychedelic compounds, like psilocybin, to
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions.
Normally when we we write about Revive Therapeutics (RVV.C), it’s generally to provide an update on their progress regarding their experimental COVID-19 palliative, Bucillamine. This
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions.
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3
The ongoing COVID-19 drama that’s dragged markets to its knees may almost be over, as finally companies have made some headway and there’s a drug
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
